XingImaging Selected as the Imaging Core Lab for the Alzheimer's Tau Platform (ATP) Phase II Clinical Trial
PR Newswire —
NEW HAVEN, Conn., Feb. 18, 2026 /PRNewswire/ -- XingImaging has been selected as the Imaging Core Lab for the Alzheimer's Tau Platform (ATP)—a groundbreaking, multi-arm, randomized Phase II clinical trial designed to simultaneously investigate multiple tau-directed therapeutic candidates...